TrialInternational journal of hematology2018

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

Naoto Takahashi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.